compani lly-
invest summari reiter ow rate price target
held invest commun meet event
keep us posit stock receiv pushback
investor stock may struggl trade higher next year
ytd valuat rel expens
ev/ebitda vs averag peer said still believ
solid execut pipelin advanc drive upward earn revis
share higher plan focu human pharma
build leadership diabet reposit oncolog franchis expand
immunolog pain invest select lead alzheim target
compani pace launch new drug year mani drug
blockbust potenti view
tirzepatid could next blockbust develop tirzepatid
diabet obes nash compani plan start phase studi
obes phase studi nash phase studi
expect start tirzepatid dual receptor agonist
plan first market year new class drug
belief tirzepatid blockbust potenti support robust data
exceed street expect glycem control weight reduct
pain import new vertic three key drug pain portfolio
includ emgal lasmiditan tanezumab focus solut
acut prevent migrain emgal lasmiditan also
emgal could one first drug approv treat cluster also known
suicid headach area larg unmet need develop
tanezumab treat oa clbp cancer pain long-term oa clbp
data come think clbp cancer pain data could show
better safeti profil seen oa may remov overhang
market opportun tanezumab cancer pain data
immunolog pipelin promis alreadi launch olumi
ra compani also look olumi alopecia areata phase
top-lin atop dermat phase top-lin system lupu
erythematosu phase top-lin also develop mirikizumab
treat psoriasi phase top-lin uc phase top-lin crohn
increas ep estim updat financi model
guidanc outlook increas ep estim
disclosur section may found page
use blend ev/ebidta dcf analysi arriv pt
greater-than-expect brand and/or gener competit lilli key drugs/product
number lilli top-sel human pharmaceut product recent lost lose
next sever year signific patent protect and/or data protect
well key countri outsid certain signific product longer
effect exclus patent protect data protect non-biolog product
loss exclus whether expir consequ litig typic result
entri one gener competitor lead rapid sever declin
revenu especi histor outsid market penetr gener
follow loss exclus rapid pervas howev gener
market penetr increas mani market outsid includ japan europ
mani countri emerg market biolog humalog humulin erbitux
cyramza trulic taltz loss exclus may may result near-term entri
competitor version biosimilar due develop timelin manufactur challeng
and/or uncertainti regulatori pathway approv competitor version
setback lilli pipelin could headwind compani futur growth prospect
lilli compet larg number multi-national pharmaceut compani biotechnolog
compani gener pharmaceut compani compet success lilli must
continu deliv market innov cost-effect product meet import medic
lilli human pharmaceut busi subject increas govern price control
public privat restrict price reimburs access drug
could materi advers effect busi public privat payer take
increasingli aggress step control expenditur human pharmaceut
place restrict price reimburs patient access lilli medic
pressur could neg affect futur revenu net incom lilli expect
price reimburs access pressur govern privat payer insid
outsid becom sever
manufactur difficulti disrupt could lead product suppli problem
anim health manufactur complex highli regul
manufactur difficulti lilli facil contract facil failur refus
contract manufactur suppli contract quantiti could result product shortag
lead lost revenu difficulti disrupt could result qualiti regulatori
complianc problem natur disast mechan inform technolog system failur
inabl obtain sole-sourc raw intermedi materi addit given difficulti
predict sale new product long lead time necessari expans
regulatori qualif pharmaceut manufactur capac possibl lilli
could difficulti meet unanticip demand new product
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casesal trulic jardianc taltz verzenio key drug exceed expectationspipelin advanc exceed expectationsstrateg accret scenario casesal trulic jardianc taltz verzenio key drug line expectationspipelin advanc line expectationsno scenario casesal trulic jardianc taltz verzenio key drug expectationspipelin advanc expectationsno scenario exhibit catalyst event calendar
datedriverupcom abemaciclib phase trial phase enrol alzheim phase efficaci safeti top-line readout oa pain studi phase long-term efficaci safeti top-line readout oa pain studi top-line readout clbp studi baricitinib phase top-line data atop dulaglutid regulatori submiss rewind top-line readout crohn ixekizumab phase top-line data non-radiograph axial spondyloarthritisjun dulaglutid present detail rewind result ada scientif ramucirumab merestinib data pivot phase trial biliari tract canceraugust exclus europ agonist phase surpass initi type diabet vs agonist phase surpass initi type diabet agonist phase surpass japan monotherapi initi type agonist phase surpass japan oad combin initi type agonist phase surpass initi type diabet vs agonist phase surpass initi type diabet basal insulin initi chronic kidney agonist initi phase studi agonist initi phase studi nash non-alcohol baricitinib phase top-line data alopecia initi crohn pegyl phase renal cell antibodyphas readout identifi biomark key kinas inhibitorphas posit alloster modul pam phase readout parkinson diseas glucagonregulatori decis /eu top-line data congest heart failur chf exercis abil ixekizumab regulatori submiss radiograph axial spondyloarthr ixekizumab regulatori action radiograph axial ixekizumab phase top-line data psoriasi head-to-head vs tremfya guselkumab olaratumab phase os readout soft tissu ramucirumab phase top-lin relay data egfr nsclc ramucirumab regulatori action high afp hepatocellular cancer lisprodata present medic meet type type galcanezumab eu regulatori submiss episod cluster galcanezumab approv episod cluster studi public scientif meet data premetrex patent litig ipr appeal premetrex patent litig altern form outcom studybegin enrol linagliptin phase top-lin data carolina cv outcom empagliflozin regulatori submiss type empagliflozin approv type empagliflozin result empris remain ownership interest agonist present full titrat studi data help manag gi side effect medic approv acut lisproregulatori submiss /eu/japan type type diabetessourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom studi overcom avail baselin dulaglutid phase top-line data altern dose type phase emperial-preserv outcom trial chronic phase emperial-reduc outcom trial chronic readout solid abemaciclib keytrudaphas data hr breast cancer kra nsclc non-squam kinase/mtor dual inhibitor prostat penregulatori submiss type type diabet late pegyl pembrolizumab cypress nsclc top-line resultsl pegyl nivolumab io nave cypress nsclc top-line readout cancer rapid lispropotenti overal surviv os top-line data agonist initi surpass cvot event driven power cv dulaglutid label updat rewind phase emperor hf-preserv outcom trial chronic phase emperor hf-reduc outcom trial chronic phase empa-kidney outcom trial chronic kidney readout alzheim readout dian pegyl folfoxphas sequoia pancreat cancer top-line readout solid abemaciclib result phase adjuv studi hr breast cancer baricitinib phase top-line data system lupu antibodyphas readout alzheim top-line data ulcer agonist phase surpass data type diabet vs glargin establish pegyl insulin deliveri systempotenti outcom studymain studi premetrex eu loss premetrex japan loss exclusivityl agonist complet phase surpass program type agonist potenti global studi overcom end data premetrex patent expir loss pediatr exclus abemaciclib nce exclus readout aspirinu patent dulaglutid patent agonist data surpass cvot event driven power cv patent patent jentaduet patent ramucirumab patent ixekizumab patent olaratumab eu loss olaratumab patent abemaciclib patent baricitinib eu patent baricitinib patent ixekizumab eu loss baricitinib japan patent galcanezumab patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
 co engag discoveri develop manufactur sale pharmaceut product oper two segment
product anim health product segment includ discoveri develop
manufactur market sale human pharmaceut product world-wide follow therapeut area neurosci
endocrinolog oncolog cardiovascular anim health segment oper divis
develop manufactur market product food companion anim anim product includ rumensin tylan
posilac paylean product livestock poultri well trifexi comforti product companion anim
